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Porcine reproductive and respiratory syndrome (PRRS) causes substantial financial
losses in pig farms and economic losses to societies worldwide. Vaccination against
PRRS virus (PRRSV) is a common intervention in affected farms. The aim of this study
was to assess the economic impact and profitability of potential new PRRS vaccines
with improved efficacy at animal, herd, and national level. Two vaccination strategies
were modeled; (i) mass vaccination of sows only (MS) and (ii) mass vaccination of sows
and vaccination of piglets (MSP), comprising different scenarios of vaccine effectiveness,
vaccine price, and vaccination coverage. A farrow-to-finish farm with 1,000 working
sows from a pig-dense region in Germany served as an example farm. Financial
benefits were obtained from gross margin analyses and were defined as difference in
gross margin between a PRRSV-infected farm without vaccination (baseline) and with
vaccination (intervention). Financial benefits were highest if both sows and piglets (MSP)
were vaccinated. In these scenarios, median annual net benefits per working sow ranged
from e170 to 340. If sows only were vaccinated (MS), estimated benefits attributable to
vaccination were betweene148 and 270. Decisive variables for the estimation of national
level benefits were the number of farmers switching from existing to a better protecting
vaccine, the number of previously non-vaccinating herds adopting the new vaccine, and
the effectiveness of the new vaccine relative to those already available. Benefits were
greatest when the new vaccine was adopted by previously non-vaccinating herds. The
analyses showed that vaccination against PRRSwas beneficial for all modeled scenarios.
The magnitude of benefits derived from vaccination was more susceptible to changes in
vaccination effectiveness than to vaccine price changes. This study provides evidence
to support future vaccine development. The estimates indicate that the introduction of
more efficient vaccines might lead to substantial financial benefits, is of socio-economic
importance and that new vaccines might significantly contribute to the reduction of
disease burden.
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INTRODUCTION
Porcine reproductive and respiratory syndrome (PRRS) causes
substantial economic losses in pig production worldwide (1–
4). In the United States, the estimated annual cost of PRRS on
the national level was estimated at US $664 million, based on
a population size of 5.8 million breeding sows and 110 million
pigs marketed per year (2). At farm level, costs due to PRRS
depend on the individual farm situation including factors such
as disease severity, affected production stages, or farm size.
Median losses in a farrow-to-finish farm in Germany with 1,000
working sows moderately affected in all production stages were
estimated at e 442′973 per year (3). Both the reproduction
component of the disease manifested in breeding sows and the
respiratory component in growing pigs contribute substantially
to the economic losses (2, 3).
Various strategies have been developed to control PRRS. Apart
from elimination procedures with the aim to create a completely
virus-negative herd (e.g., closure and roll-over) or improvement
of biosecurity and management, vaccination against PRRS is a
common approach to control the disease (5). Depending on
individual farm situation, several intervention strategies have
shown to be profitable, with mass vaccination of sows or mass
vaccination of sow and piglets being amongst the most cost
efficient control strategies (6).
Besides the commercially available inactivated vaccines
and modified-live virus vaccines (MLV), new techniques for
administration have been explored and developed and research
on the use of DNA vaccines to further improve efficacy of MLV
vaccines has been conducted (7–9). However, current vaccines
fail to provide complete protection against heterologous field
strains and commercially available vaccines only partially prevent
or mitigate the disease and show limited effectiveness in the
field (10–13).
Most literature on vaccine efficacy describes effects under
ideal study conditions. Typically, vaccine efficacy is assessed in
experimentally infected pigs and refers to clinical, virological,
or pathological findings after challenge under experimental
conditions. Outcomes are reported as reduction of viremia
in terms of duration and/or magnitude, of clinical signs
or of pathological lesions (11, 14). Moreover, vaccine
effectiveness might also be considered by epidemiological
parameters describing disease dynamics and a reduction in virus
transmission (15, 16).
Literature on vaccination effectiveness in the field and the
impact on production parameters is scarce (17). However,
this information is needed for farmers to convert positive
effects of vaccination into monetary values and to estimate
financial benefits through economic assessments and gross
margin analyses (18). Moreover, the benefit of a vaccine in
relation to its cost and thus vaccine price and return on
investment are determining factors that influence farmer’s
attitude and willingness to pay for a vaccine (19). When trying
to estimate financial benefits on a national level, these are
important aspects, which might affect vaccination coverage and
the proportion of farmers adopting a new vaccine. With these
preconditions, scenario modeling and stochastic simulations are
common approaches used to account for missing information
and uncertainty.
The aim of this study was to assess economic effects
associated with vaccination against PRRS and to estimate
financial benefits on animal, herd, and national level. To evaluate
the impact of various vaccine characteristics, different levels of
vaccination effectiveness, vaccine price, and vaccination coverage
were modeled.
MATERIALS AND METHODS
Model Description
The economic assessment of vaccination against PRRS is based
on a stochastic model developed by Nathues et al. (3). The initial
model estimated the financial burden of disease in endemically
PRRSV-infected farms and served as baseline to model the
economic efficiency of different control strategies against PRRS
(6). To estimate the potential financial benefit of different vaccine
characteristics and vaccination scenarios within this project,
the initial model was adapted and expanded accordingly. The
model was built in Excel (Microsoft Corporation, Redmont,
Washington, USA) and the Add-on @Risk was used (Palisade
Corporation, Newfield, New York, USA) to account for
uncertainty and variability of parameters. The spreadsheet
model consisted of several sub-models, which were linked
with each other. Production parameters and epidemiological
effects were identified and assessed in a literature review and
implemented into the initial model. The production model
simulated production dynamics within a timeframe of one
year. The epidemiological flow model simulated disease impact
according to defined disease status and incorporated these effects
into the production model. In the intervention model, the cost
and effectiveness associated with different vaccine characteristics
and intervention strategies were defined and linked with the
production and epidemiological model. The economic impact
of disease and intervention was assessed by performing a gross
margin analysis using production model outputs. The gross
margin was defined as the total revenue minus variable cost.
Variable cost consisted of replacement cost, market prices for
sold or slaughtered animals, feeding cost, veterinary cost, cost for
disposal of dead animals, variable energy cost, and miscellaneous
cost. Full details of the baseline model, including prices of
economic parameters, can be obtained fromNathues et al. (3) and
the Supplementary Material. Stochastic simulations were run
with 1,000 iterations per scenario. For the most part, stochastic
model outputs were not normally distributed and estimates are,
unless stated otherwise, reported as medians.
Farm Description
To model economic effects at farm-level, a typical farrow-to-
finish farm from a pig-dense region in Germany was chosen
to serve as an example farm. As this farm type contains all
three production stages (breeding, nursing, and fattening), it
was possible to capture financial effects for each of the three
production parts separately. Furthermore, this approach permits
that the model could also be used for economic evaluations of
farms that only have one or two of the production parts (i.e.,
Frontiers in Veterinary Science | www.frontiersin.org 2 August 2020 | Volume 7 | Article 500
Thomann et al. Economic Assessment of PRRS Vaccination
TABLE 1 | Farm characteristics of the example farrow-to-finish farm used for the
economic model.
Parameter Value
Number of working sows 1,000
Production rhythm (weeks) 3
Duration of suckling period (weeks) 3
Replacement rate (%) 35
Feed consumption during gestation (kg) 275
Feed consumption during lactation (kg) 200
Downtime between turns in nursery pens (days) 2
Downtime between turns in fattening pens (days) 5
Weight after nursery (kg) 30
Weight at slaughter (kg) 120
breeding herd with the sale of weaners, breeding herd with the
sale of nursery pigs, nursery only, fattening only). The example
farm has 1,000 working sows, batch-wise farrowing every week,
3 weeks suckling period, an annual replacement rate of 35%, and
finishers are sold at 120 kg live weight. A detailed description of
farm characteristics is listed in Table 1. For the disease impact
estimation, it was assumed that field virus was newly detected in
a farm endemically infected with PRRSV. The farm previously
did not vaccinate against PRRS and both reproduction and
respiratory components of the disease were present in the herd.
Consequently, it was expected that clinical effects would occur
in all production parts along with reduced performance and
production output in breeding, nursing, and fattening. Values
of production parameters of a PRRS negative farm, a PRRSV-
infected farm, and absolute disease effects are listed in Table 2.
Negative farm data was obtained from industry reports (20,
21) whereas information on the magnitude of disease effects
in endemically PRRSV-infected farms was assessed through an
expert poll conducted within the study framework of the initial
model (3). Out of various scenarios with different levels of disease
severity described in the initial model, a moderate scenario with
median values for clinical affectedness was selected to serve as
basis for the conducted analyses.
Vaccination Strategies and Vaccine
Characteristics
Two different vaccination strategies were considered in the
model: (i) mass vaccination of sows only (MS) and (ii) mass
vaccination of sows and vaccination of piglets (MSP). For MS,
the vaccination protocol comprised a basic immunization of all
sows and a booster vaccination 4 weeks later. After this, the entire
sow herd is periodically vaccinated every 3 month. Incoming gilts
are vaccinated twice during acclimatization. The MSP strategy
is following the same protocol as the MS but with additional
vaccination of piglets between the ages of 2–3 weeks.
The twomain vaccine characteristics and associated economic
effects examined in this study were vaccination effectiveness
and vaccine price. For the economic modeling, the vaccination
effectiveness was defined as the proportion by which disease
effects in production parameters would be reduced after
TABLE 2 | Production parameters with assumed values of a PRRS negative farm
and a PRRSV-infected farm with corresponding absolute disease effects.
Parameter Negative
farm
Infected
farm
Disease
effect
Return-to-oestrus rate 10.0% 13.5% +3.5%
Abortion rate 2.0% 3.9% +1.9%
Average piglets born alive
per sow and litter
12.7 11.4 −1.3
Pre-weaning mortality 11.0% 13.5% +2.5%
Weight at weaning 6.0 kg 5.5 kg −0.5 kg
Days in nursery 45 days 50 days +5 days
PRRS morbidity in weaners – 20.0% +20.0%
Mortality in weaners 3.0% 10.0% +7.0%
Days in fattening 119 127 days +8 days
PRRS morbidity in fatteners – 20.0% +20.0%
Mortality in fatteners 1.5% 3.0% +1.5%
vaccination. Thus, related data on the improved of production
output was required for implementation into the production
model. The effectiveness of a vaccine when deployed in the
field depends not only on the vaccine efficacy under ideal
conditions but also on the characteristics of the population to
whom it is administered and the comparison population (14).
Since no evidence-based data was available, different levels of
vaccination effectiveness were modeled: 50, 60, 70, 80, and
90%. In this context, an assumed vaccination effectiveness of
80% would mean the following: If the baseline abortion rate
in a PRRS negative farm is 2% and in a PRRSV-infected farm
3.9%, the absolute disease effect is +1.9% (Table 1). Vaccination
would reduce disease effects by 80% (−1.52%) and the abortion
rate would persist at 2.38% after vaccination. To account for
uncertainty and variation of vaccine price, several scenarios with
different price levels were modeled: e0.75, 1.00, 1.25, and 1.50.
The vaccine price was defined as the price per dose (including
labor) for the single vaccination of one sow. For the MSP
strategy, vaccination of a piglet would cost 80% of the price of
sow vaccination.
National-Level Analyses and Vaccination
Coverage
The estimation of national-level benefits was based on outcomes
from farm-level analyses. Demographic data on the pig
population in Germany was obtained from the Federal Statistical
Office (22). Overall, there are 27.2 million pigs, located on 23,800
farms. Of these, 8,400 farms hold breeding sows with totally 1.9
million sows. Herd-level prevalence show regional differences
and is estimated to be between 50 and 100%, with high prevalence
particularly in pig dense regions (23).
For the analyses, the breeding sow population was divided into
two groups: previously vaccinated sows (preVS) and previously
non-vaccinated sows (pnonVS). Previously vaccinated sows were
defined as sows that were vaccinated against PRRS with a licensed
and commercially available vaccine in the past. On the other
hand, pnonVS were defined as sows that were not vaccinated
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against PRRS yet. The proportion of preVS is equivalent to the
initial vaccination coverage whereas the proportion of pnonVS
is equal to one minus the vaccination coverage. No empiric data
on vaccination coverage was available and consequently different
levels of preVS and pnonVS were modeled to account for
uncertainty of this parameter. The proportion of sows that were
vaccinated with a potential new vaccine (nVac) was independent
from vaccination coverage and could be different in preVS and
pnonVS. In preVS, it described the switch from a previously
used licensed vaccine to nVac, whereas in pnonVS it described
the switch from not vaccinating sows to newly vaccinating sows
using nVac.
Different levels of vaccination effectiveness were modeled in
the national-level analyses. For pnonVS, these comprised 50, 60,
70, 80, and 90%. For preVS, vaccination effectiveness of nVac was
expressed as absolute change in effectiveness and five levels were
considered (+5, +10, +15, +20, and +25%). For example, an
effectiveness of+5% implied that disease effects were reduced by
an additional 5%, compared to the previously used vaccine. To
estimate financial benefits at national level, individual benefits
per breeding sow were extrapolated. Animal-level benefits used
as input values were obtained from farm-level analyses and
were then multiplied by the corresponding number of affected
animals. For national-level analyses, vaccine price was fixed ate1
for all scenarios.
RESULTS
Financial losses due to PRRS, expressed as difference in gross
margin between a PRRSV negative and a PRRSV-infected farrow-
to-finish farm with disease effects according to Table 2 and
1,000 working sows were e400,018 per year (Figure 1). The
median farm-level financial benefit attributable to vaccination
with nVac ranged from e147,525 to 269,759 when sows only
are vaccinated (Table 3) and from e169,563 to 339,643 in
the MSP strategy, when piglets are also vaccinated (Table 4).
Consequently, annual animal-level benefits per working sow
attributable to vaccination were estimated to be between e148
and 270 for MS (Figure 2) and between e170 and 340 for
MSP (Figure 3). These two figures give an overview of the
associations between the modeled vaccine characteristics and
financial benefits per working sow. The magnitude of financial
benefits generated was more sensitive to a change in vaccination
effectiveness than the variation of vaccine price. Particularly
TABLE 3 | Differences in annual gross margin (in e) between a PRRSV-infected
farm without intervention and a PRRS-infected farm with mass vaccination of
sows (MS).
Vaccine price Vaccination effectiveness
50% 60% 70% 80% 90%
e0.75 150′727 179′865 209′149 239′455 269′759
e1.00 149′581 178′387 208′127 238′336 268′272
e1.25 148′313 177′482 207′020 237′136 267′480
e1.50 147′525 176′312 205′959 235′820 266′435
TABLE 4 | Differences in annual gross margin (in e) between a PRRSV-infected
farm without intervention and a PRRSV-infected farm with mass vaccination of
sows and piglets (MSP).
Vaccine price Vaccination effectiveness
50% 60% 70% 80% 90%
e0.75 188′938 225′481 262′646 300′798 339′643
e1.00 182′137 218′858 255′985 293′787 332′766
e1.25 175′883 211′992 249′089 287′053 325′839
e1.50 169′563 205′473 242′660 280′265 319′222
FIGURE 1 | Annual gross margins for a PRRS negative farm, a PRRSV-infected farm without vaccination (“diseased”) and a PRRSV-infected farm with vaccination
(MS and MSP strategy).
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FIGURE 2 | Annual benefit per working sow, depending on vaccination effectiveness, and vaccine price, when vaccinating sows only (MS strategy) against PRRS.
FIGURE 3 | Annual benefit per working sow, depending on vaccination effectiveness, and vaccine price, when vaccinating sows and piglets (MSP strategy) against
PRRS.
in the MS strategy, vaccine price had only minor effects on
the profitability, whereas effects were more pronounced when
piglets are vaccinated as well. For all modeled scenarios, the MSP
strategy was more beneficial than MS when identical vaccine
characteristics were assumed.
Financial benefits at national level were generated by adopting
nVac to both preVS and pnonVS. Outputs were dependent on the
variation of vaccination effectiveness, vaccination coverage, and
the proportion of sows newly vaccinated with nVac.
In preVS, for each sow newly vaccinated with nVac, a
median benefit of e3 was gained for every +1% of increased
effectiveness compared with the effectiveness of the previously
used vaccine. National-level financial benefits ranged from e2.3
to 45.7 million for the listed scenarios and a fixed vaccination
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effectiveness of +10% (Table 5). As an example, if 30% of sows
were newly vaccinated with nVac and vaccination coverage was
60%, the annual financial benefit was estimated to be e10.3
million. If vaccination coverage was fixed at 60% and vaccination
effectiveness varied from +5 to +25%, the financial benefit
ranged from e1.7 to 85.8 million (Table 6). The proportion of
sows newly vaccinated with nVac had a substantial effect on
the magnitude of financial benefit, especially when effectiveness
increased (Figure 4).
In pnonVS, financial benefits per sow were substantially
higher than in preVS. Median benefits per sow ranged frome150
to 268, depending on vaccination effectiveness and at a fixed
vaccine price of e1. Already a small number of pnonVS newly
vaccinated with nVac generated significant benefits at national
level. If vaccination effectiveness varied between 50 and 90%
and between 1 and 10% of sows were vaccinated with nVac,
financial benefits ranged from e2.9 to 51.1 million (Table 7). If
initial vaccination coverage was 50% and all of the pnonVS would
TABLE 5 | Financial benefits (in e) associated with vaccination of previously
vaccinated sows (preVS), when vaccination effectiveness of a potential new
vaccine (nVac) is +10% compared to the previously used alternative vaccine.
Proportion of
nVac in preVS
Vaccination coverage
40% 50% 60% 70% 80%
10% 2′287′440 2′859′300 3′431′160 4′003′020 4′574′880
20% 4′574′880 5′718′600 6′862′320 8′006′040 9′149′760
30% 6′862′320 8′577′900 10′293′480 12′009′060 13′724′640
40% 9′149′760 11′437′200 13′724′640 16′012′080 18′299′520
50% 11′437′200 14′296′500 17′155′800 20′015′100 22′874′400
60% 13′724′640 17′155′800 20′586′960 24′018′120 27′449′280
70% 16′012′080 20′015′100 24′018′120 28′021′140 32′024′160
80% 18′299′520 22′874′400 27′449′280 32′024′160 36′599′040
90% 20′586′960 25′733′700 30′880′440 36′027′180 41′173′920
100% 22′874′400 28′593′000 34′311′600 40′030′200 45′748′800
Estimates depend on vaccination coverage and the proportion of preVS that are newly
vaccinated with nVac.
TABLE 6 | Financial benefits (in e) due to vaccination of previously vaccinated
sows (preVS) with nVac instead of a previously used licensed vaccine (vaccination
coverage fixed at 60%).
Proportion of
nVac in preVS
Vaccination effectiveness
+5% +10% +15% +20% +25%
10% 1′715′580 3′431′160 5′146′740 6′862′320 8′577′900
20% 3′431′160 6′862′320 10′293′480 13′724′640 17′155′800
30% 5′146′740 10′293′480 15′440′220 20′586′960 25′733′700
40% 6′862′320 13′724′640 20′586′960 27′449′280 34′311′600
50% 8′577′900 17′155′800 25′733′700 34′311′600 42′889′500
60% 10′293′480 20′586′960 30′880′440 41′173′920 51′467′400
70% 12′009′060 24′018′120 36′027′180 48′036′240 60′045′300
80% 13′724′640 27′449′280 41′173′920 54′898′560 68′623′200
90% 15′440′220 30′880′440 46′320′660 61′760′880 77′201′100
100% 17′155′800 34′311′600 51′467′400 68′623′200 85′779′000
newly be vaccinated with nVac, financial benefits would range
frome143 to 256million, depending on vaccination effectiveness
(Figure 5).
DISCUSSION
Results from this study demonstrate that the introduction of nVac
is associated with substantial financial benefits at animal, farm,
and national level.
When interpreting farm-level outcomes it has to be
considered that the estimated benefits are reported as differences
in grossmargin between a PRRSV-infected herd without previous
intervention and a PRRSV-infected herd with intervention, in
the form of vaccination. Furthermore, it was assumed that all
production parts were affected by PRRS, which was associated
with substantially reduced production performance and farm
output and thus farm revenue. Therefore, it has to be taken into
account that in practice it is likely that a farm showing such
magnitudes of disease effects would already have implemented
some sort of disease control, possibly in the form of vaccination
with an already licensed and commercially available vaccine.
This would imply that financial benefits of using nVac would
have to be obtained from comparing farms vaccinating with
nVac and farms vaccinating with an “old” vaccine. Consequently,
reported estimates represent the maximum possible benefits
based on the situation when no previous disease control was
established. Financial benefits in farms that switch from an
alternative vaccine to nVac are less pronounced, as demonstrated
in the national-level models.
Estimates from this study are based on an example farm
where both reproductive and respiratory traits were affected
by PRRS. The reproduction parameters “abortion rate” and
“number of piglets born alive” had a significant impact on gross
margin. When an increased number of piglets are born due to
improved reproductive performance after vaccination, more pigs
go through the different production stages and eventually more
fatteners are sold for slaughter. This had a direct impact on the
farm output and consequently led to higher farm revenue. A
main effect of the respiratory component of the disease is the
reduced performance of growing pigs (24, 25). This effect is also
reflected in the finding that the MSP strategy is more profitable
than the MS. The additional cost for the piglet vaccination
was compensated and surpassed by the improved production
performance in the nursery and fattening stage.
The sensitivity analysis showed that the gross margin
and associated economic profitability were more sensitive to
vaccination effectiveness than to vaccine price. However, the
range of vaccine prices included in the scenarios was limited.
A potential novel vaccine stands in competition with other
PRRS vaccines (7) and therefore its price would be influenced
by the price of the already commercially available vaccines.
Furthermore, it is likely that vaccination effectiveness and vaccine
price are correlated. If vaccination effectiveness is high, farmers
might be willing to pay more and when farmers can chose
between different products, they would only purchase vaccines
that are more expensive if vaccination effectiveness is increased
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FIGURE 4 | Financial benefit associated with vaccination of previously vaccinated sows (preVS), when vaccination coverage is 60%, and vaccination effectiveness of
nVac ranges from +5 to +25%.
TABLE 7 | Financial benefits (in e) associated with vaccination of previously
non-vaccinated sows (pnonVS) for different levels of vaccination effectiveness and
proportion of newly vaccinated sows.
Proportion of
sows vaccinated
with nVac
Vaccination effectiveness
50% 60% 70% 80% 90%
1% 2′851′317 3′400′409 3′967′309 4′543′155 5′113′805
2% 5′702′634 6′800′818 7′934′618 9′086′310 10′227′609
3% 8′553′951 10′201′228 11′901′928 13′629′465 15′341′414
4% 11′405′267 13′601′637 15′869′237 18′172′620 20′455′219
5% 14′256′584 17′002′046 19′836′546 22′715′776 25′569′023
6% 17′107′901 20′402′455 23′803′855 27′258′931 30′682′828
7% 19′959′218 23′802′864 27′771′165 31′802′086 35′796′633
8% 22′810′535 27′203′273 31′738′474 36′345′241 40′910′437
9% 25′661′852 30′603′683 35′705′783 40′888′396 46′024′242
10% 28′513′168 34′004′092 39′673′092 45′431′551 51′138′047
accordingly (26). Overall, a “vaccine cost-benefit ratio,” expressed
as vaccine price compared to its vaccination effectiveness, could
serve as key criteria in farmer’s decision-making process. This
implies that even if the vaccination effectiveness of nVac would be
lower than the effectiveness of alternative vaccines, farmers might
still switch to nVac under certain circumstances. Consequently,
setting a market price for nVac without knowing its effectiveness
in the field would be associated with a high level of uncertainty
and thus different scenarios were modeled. In addition, market
prices of vaccines do not only depend on its effectiveness alone,
but do include many other criteria and are defined in a multi-
step procedure (27) which implies that vaccine prices used in
this model do not permit conclusions about production cost or
margins of the vaccine manufacturer.
The results indicate that benefits generated in pnonVS are
significantly higher than in preVS. This is because infected
pnonVS showed substantially reduced production performance
prior to vaccination whereas disease effects in preVS were already
diminished due to vaccination with an alternative vaccine.
However, the contribution to the overall financial benefit might
still be larger from preVS than from pnonVS. It is likely that
in practice, the proportion of sows newly vaccinated with nVac
might be substantially higher in preVS than in pnonVS. It might
be more challenging to convince farmers to start vaccinating
their sows against PRRS (and chose nVac) than convincing
farmers that already have been vaccinating their sows to switch to
nVac. These farmers are already familiar with PRRS vaccination,
associated cost, labor, and equipment and thus might be more
likely to start using a new vaccine (28). A further point for
discussion is the impact of nVac on the market equilibrium,
associated with reduced disease prevalence (29). If a large
proportion of farmers were vaccinating their sows, production
performance would increase, more pigs would be marketed and
eventually supply increases. This would lead to a shift of the
supply curve and a change of market equilibrium associated with
lower prices for farmers (30). However, market impacts were not
considered in this study.
In the context of scenario analysis, reported financial benefits
for different scenarios modeled in this study do not consider
the plausibility of the corresponding scenario. The likelihood of
a certain scenario has to be further investigated and supported
with empiric data as no information on current vaccination
coverage or public data on market shares of existing PRRS
vaccines is available. Moreover, without yet knowing vaccination
effectiveness and vaccine price, it is difficult to estimate to what
extent nVac would be adopted in the field. The proportion
of farmers that would switch from an alternative vaccine to
nVac, as well as the proportion of farmers who would newly
start vaccinating against PRRS, significantly depend on these
key vaccine characteristics. Therefore, potential socio-economic
benefits largely depend on farmers’ attitude toward PRRS
vaccination and their decisions with respect to switching to a new
vaccine (31). The behavior of a few single farmers might have a
significant impact at national level, depending on their farm size.
In Germany, farm sizes are rather heterogeneous (22). There are
Frontiers in Veterinary Science | www.frontiersin.org 7 August 2020 | Volume 7 | Article 500
Thomann et al. Economic Assessment of PRRS Vaccination
FIGURE 5 | Financial benefit associated with vaccination of previously non-vaccinated sows (pnonVS) for different levels of vaccination effectiveness and proportions
of newly vaccinated sows.
many small farms and only few large pig farms. When looking at
breeding farms, 24% of them have<50 sows but account for only
2% of the population. On the other hand, only 8% of farms have
more than 500 sows but make up for 42% of all breeding sows in
Germany. This implies that if a few owners of large farms decide
to switch to nVac, a considerable number of sows are affected.
However, the decision to switch to nVac might not only be a
farmers’ own choice. The decision-making process might also be
influenced and controlled by a number of external factors (28).
CONCLUSIONS
The analysis performed showed that while vaccination against
PRRS was beneficial for all modeled scenarios, vaccinating both
sows and piglets proved to be more profitable than vaccinating
sows alone. The magnitude of benefits derived from vaccination
was more sensitive to changes in vaccine effectiveness than to
vaccine price changes. Actual economic benefits of nVac largely
depend on the extent to which it would be adopted in the field
and consequently also on farmer’s attitude toward a new vaccine
and willingness to pay.
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